CA
MRNA icon

Clearstead Advisors’s Moderna MRNA Stock Holding History

Clearstead Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.4K Buy
906
+797
+731% +$41.2K ﹤0.01% 1422
2026
Q1 		$5.54K Sell
109
-32
-23% -$1.49K ﹤0.01% 1722
2025
Q4 		$4.16K Buy
141
+11
+8% +$299 ﹤0.01% 2049
2025
Q3 		$3.36K Buy
130
+21
+19% +$586 ﹤0.01% 2303
2025
Q2 		$3.01K Sell
109
-11
-9% -$290 ﹤0.01% 2242
2025
Q1 		$3.4K Buy
120
+8
+7% +$284 ﹤0.01% 1804
2024
Q4 		$4.66K Buy
112
+5
+5% +$239 ﹤0.01% 1734
2024
Q3 		$7.15K Sell
107
-2,438
-96% -$224K ﹤0.01% 1649
2024
Q2 		$302K Buy
2,545
+2,438
+2,279% +$309K 0.01% 677
2024
Q1 		$13.4K Sell
107
-21
-16% -$2.12K ﹤0.01% 1012
2023
Q4 		$12.7K Sell
128
-208
-62% -$17.5K ﹤0.01% 1021
2023
Q3 		$34.7K Sell
336
-12
-3% -$1.34K ﹤0.01% 787
2023
Q2 		$42.3K Sell
348
-1,307
-79% -$174K ﹤0.01% 762
2023
Q1 		$254K Buy
1,655
+905
+121% +$149K 0.02% 358
2022
Q4 		$135K Hold
750
– – 0.01% 441
2022
Q3 		$89K Sell
750
-24
-3% -$3.64K 0.01% 499
2022
Q2 		$111K Buy
774
+420
+119% +$60K 0.01% 484
2022
Q1 		$61K Hold
354
– – ﹤0.01% 645
2021
Q4 		$90K Buy
354
+125
+55% +$36.5K 0.01% 550
2021
Q3 		$88K Sell
229
-10
-4% -$3.69K 0.01% 511
2021
Q2 		$56K Hold
239
– – ﹤0.01% 535
2021
Q1 		$31K Sell
239
-6
-2% -$869 ﹤0.01% 605
2020
Q4 		$26K Sell
245
-130
-35% -$13.2K ﹤0.01% 594
2020
Q3 		$27K Buy
375
+330
+733% +$23K ﹤0.01% 553
2020
Q2 		$3K Buy
+45
New +$2.46K ﹤0.01% 710

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Clearstead Advisors's MRNA Position: Q2 2026 in Review

Clearstead Advisors increased its Moderna (MRNA) stake by 731% in Q2 2026, buying an estimated $41.2K and bringing the position to 906 shares worth $63.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1422.

Clearstead Advisors first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $302K in Q2 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Clearstead Advisors held 906 shares of Moderna worth $63.4K as of Q2 2026.
  • Clearstead Advisors bought 797 Moderna shares in Q2 2026, an estimated $41.2K.
  • Moderna made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1422 holding.
  • Clearstead Advisors first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Clearstead Advisors's Moderna position peaked at $302K in Q2 2024.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.